Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29864580 | 0.72 | TDP1 (0.38) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL1651160 | 0.72 | PDPK1 (0.42) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL5457433 | 0.72 | CRHBP (0.37) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL6676223 | 0.72 | CRHBP (0.40) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL5066814 | 0.72 | TDP1 (0.38) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL30361763 | 0.72 | PDPK1 (0.42) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL8650175 | 0.71 | NUDT1 (0.41) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL6676030 | 0.69 | PDE5A (0.41) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL6676368 | 0.69 | CRHBP (0.49) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL6909696 | 0.69 | SORD (0.36) | CRHBPCRHR2KEAP1NFE2L2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | claimed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | claimed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
| EP-0972517-B1 | Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumors | UNIV LELAND STANFORD JUNIOR (US) | 2004-07-07 | — | — | EP | disclosed |
| US-6277835-B1 | ADMINISTERING SYNERGISTIC DOSAGE OF A 1,2,4-BENZOTRIAZINE OXIDE COMPOUND CYTOLYTIC AGENT EFFECTIVE AGAINST HYPOXIC TUMOR CELLS AND AN ANTITUMOR AGENT EFFECTIVE AGAINST OXYGENATED TUMOR CELLS | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY | 2001-08-21 | — | — | US | disclosed |
| US-6121263-A | Method of tumor treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0649658-B1 | Use of 1,2,4-benzotriazine oxides for the manufacture of a medicament for the treatment of tumors | UNIV LELAND STANFORD JUNIOR (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0972517-A2 | Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumours | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5670502-A | Method of tumor treatment | THE BOARD OF TRUSTEES OF LELAND STANFORD JR. UNIV. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5484612-A | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1996-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | CRHBP 4700/4885CRHR2 3115/4885KEAP1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.